Technology Insight: Small, noncoding RNA molecules as tools to study and treat endocrine diseases

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 12, 2007, Pages 827-834

  Kolfschoten, Ingrid G M ^a,b   Regazzi, Romano ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Department of Biochemistry ^*  (Switzerland)

Author keywords

Endocrine disease; miRNA; Novel targets; RNA interference; Therapeutic potential

Indexed keywords

MICRORNA; SMALL INTERFERING RNA; UNTRANSLATED RNA;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; GENE EXPRESSION; HUMAN; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA TRANSLATION;

ANIMALS; ENDOCRINE SYSTEM DISEASES; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNA, UNTRANSLATED; TECHNOLOGY, PHARMACEUTICAL;

EID: 36349007520     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0674     Document Type: Review

References (83)

1. Fire A et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811
2. Elbashir SM et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498
3. Novina CD and Sharp PA (2004) The RNAi revolution. Nature 430: 161-164
4. Cai X et al. (2004) Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957-1966
5. Lee Y et al. (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23: 4051-4060
6. Lee Y et al. (2003) The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419
7. Yi R et al. (2003) Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 17: 3011-3016
8. Lund E et al. (2004) Nuclear export of microRNA precursors. Science 303: 95-98
9. Ambros V (2004) The functions of animal microRNAs. Nature 431: 350-355
10. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297
11. Bagga S et al. (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 122: 553-563
12. Wu L et al. (2006) MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci U S A 103: 4034-4039
13. Doench JG and Sharp PA (2004) Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511
14. Petersen CP et al. (2006) Short RNAs repress translation after initiation in mammalian cells. Mol Cell 21: 533-542
15. Pillai RS et al. (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126
16. Mathonnet G et al. (2007) MicroRNA inhibition of translation initiation in vitro by targeting the Cap-binding complex eIF4F. Science 317: 1764-1767
17. Griffiths-Jones S et al. (2005) Rfam: annotating noncoding RNAs in complete genomes. Nucleic Acids Res 33: D121-D124
18. Gong H et al. (2005) The role of small RNAs in human diseases: potential troublemaker and therapeutic tools. Med Res Rev 25: 361-381
19. Lu J et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838
20. Voorhoeve PM et al. (2006) A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 124: 1169-1181
21. Bottoni A et al. (2005) miR-15a and miR-16-1 downregulation in pituitary adenomas. J Cell Physiol 204: 280-285
22. Fan X et al. (2001) Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genet Cytogenet 128: 97-103
23. Roldo C et al. (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24: 4677-4684
24. He H et al. (2005) The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A 102: 19075-19080
25. Kitamura Y and Hirotab S (2004) Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61: 2924-2931
26. Esau C et al. (2004) MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 279: 52361-52365
27. Poy MN et al. (2004) A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432: 226-230
28. Plaisance V et al. (2006) MicroRNA-9 controls the expression of granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 281: 26932-26942
29. Baroukh N et al. (2007) MicroRNA-124a regulates Foxa2 expression and intracellular signaling in pancreatic β-cell lines. J Biol Chem 282: 19575-19588
30. He A et al. (2007) Over-expression of miR-29, highly upregulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol [doi: 10.1210/me.2007-0167]
31. Esau C et al. (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98
32. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245-262
33. Salvatore G et al. (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12: 1623-1629
34. Kodama Y et al. (2005) The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96: 143-148
35. Berns K et al. (2004) A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428: 431-437
36. Paddison PJ et al. (2004) A resource for large-scale RNA-interference-based screens in mammals. Nature 428: 427-431
37. Kolfschoten IG et al. (2005) A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 121: 849-858
38. Westbrook TF et al. (2005) A genetic screen for candidate tumor suppressors identifies REST. Cell 121: 837-848
39. Tang X et al. (2006) An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport. Proc Natl Acad Sci U S A 103: 2087-2092
40. Abel ED et al. (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409: 729-733
41. Taniguchi CM et al. (2005) Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115: 718-727
42. Koo SH et al. (2004) PGC-1 promotes insulin resistance in liver through PPAR-α-dependent induction of TRB-3. Nat Med 10: 530-534
43. Cho CY et al. (2006) Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab 3: 367-378
44. Song E et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 9: 347-351
45. Hamar P et al. (2004) Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. Proc Natl Acad Sci U S A 101: 14883-14888
46. Bradley SP et al. (2005) Gene silencing in the endocrine pancreas mediated by short-interfering RNA. Pancreas 31: 373-379
47. Morrissey DV et al. (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23: 1002-1007
48. Urban-Klein B et al. (2005) RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12: 461-466
49. Hu-Lieskovan S et al. (2005) Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 65: 8984-8992
50. Soutschek J et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178
51. Zimmermann TS et al. (2006) RNAi-mediated gene silencing in non-human primates. Nature 441: 111-114
52. Kumar P et al. (2007) Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43
53. Song E et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709-717
54. Williams BR (1999) PKR; a sentinel kinase for cellular stress. Oncogene 18: 6112-6120
55. Sledz CA et al. (2003) Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 5: 834-839
56. Judge AD et al. (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23: 457-462
57. Hornung V et al. (2005) Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11: 263-270
58. Kim DH et al. (2004) Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol 22: 321-325
59. Persengiev SP et al. (2004) Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs). RNA 10: 12-18
60. Ma Z et al. (2005) Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 330: 755-759
61. Saxena S et al. (2003) Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 278: 44312-44319
62. Hutvagner G et al. (2004) Sequence-specific inhibition of small RNA function. PLoS Biol 2: e98
63. Meister G et al. (2004) Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 10: 544-550
64. Krutzfeldt J et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438: 685-689
65. Check E (2005) A crucial test. Nat Med 11: 243-244
66. McFarland TJ et al. (2004) Gene therapy for proliferative ocular diseases. Expert Opin Biol Ther 4: 1053-1058
67. Bitko V et al. (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11: 50-55
68. Parikh H et al. (2007) TXNIP regulates peripheral glucose metabolism in humans. PLoS Med 4: e158
69. Haasch D et al. (2006) PKCθ is a key player in the development of insulin resistance. Biochem Biophys Res Commun 343: 361-368
70. Sajan MP et al. (2006) Repletion of atypical protein kinase C following RNA interference-mediated depletion restores insulin-stimulated glucose transport. J Biol Chem 281: 17466-17473
71. Akpinar P et al. (2005) Tmem27: a cleaved and shed plasma membrane protein that stimulates pancreatic β cell proliferation. Cell Metab 2: 385-397
72. Schisler JC et al. (2005) The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet β cells. Proc Natl Acad Sci U S A 102: 7297-7302
73. Garnett KE et al. (2005) Differential gene expression between Zucker fatty rats and Zucker diabetic fatty rats: a potential role for the immediate-early gene Egr-1 in regulation of β cell proliferation. J Mol Endocrinol 35: 13-25
74. Katayama K et al. (2004) RNA interfering approach for clarifying the PPARγ pathway using lentiviral vector expressing short hairpin RNA. FEBS Lett 560: 178-182
75. Zhou QL et al. (2004) Analysis of insulin signalling by RNAi-based gene silencing. Biochem Soc Trans 32: 817-821
76. Diaferia G et al. (2004) RNA-mediated interference indicates that SEL1L plays a role in pancreatic β-cell growth. DNA Cell Biol 23: 510-518
77. Jiang ZY et al. (2003) Insulin signaling through Akt/ protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc Natl Acad Sci USA 100: 7569-7574
78. Waselle L et al. (2003) Involvement of the Rab27 binding protein Slac2c/MyRIP in insulin exocytosis. Mol Biol Cell 14: 4103-4113
79. Zablewska B et al. (2003) Transcription regulation of the multiple endocrine neoplasia type 1 gene in human and mouse. J Clin Endocrinol Metab 88: 3845-3851
80. Yart A et al. (2005) The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 25: 5052-5060
81. Riss D et al. (2003) Differential expression of galectin-3 in pituitary tumors. Cancer Res 63: 2251-2255
82. Shi Y et al. (2006) Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 91: 2373-2379
83. Sorrentino R et al. (2005) Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 90: 928-935